Loading...
Docoh
Log in Free sign up

Integrated Biopharma (INBP)

Integrated BioPharma, Inc. engages in the manufacture, distribution, marketing, and sale of vitamins, nutritional supplements and herbal products. It operates through the following segments: Contract Manufacturing, Branded Proprietary Products, and Other Nutraceutical Businesses. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers. The Branded Proprietary Products segment distributes nutritional products through mass market, grocery, drug and vitamin retailers. The Other Nutraceutical Businesses segment sells private label MDC products, as well as AgroLabs products. The company was founded by E. Gerald Kay in March 1980 and is headquartered in Hillside, NJ.

Company profile

Ticker
INBP
Exchange
NASDAQ
Website
www.ibiopharma.com
CEO
Riva Kay Sheppard / Christina Kay
Employees
Incorporated
Delaware
Location
New Jersey
Fiscal year end
Jun 30
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...
Former names
CHEM INTERNATIONAL INC, INTEGRATED HEALTH TECHNOLOGIES INC
SEC CIK
0001016504
Corporate docs
Subsidiaries
Manhattan Drug Company, Inc. • AgroLabs, Inc. • IHT Health Products, Inc. • Vitamin Factory, Inc. • IHT Properties, Inc. • MDC Warehousing and Distribution, Inc. • InB:Paxis Pharmaceuticals, Inc. ...
IRS number
222407475

INBP stock data

Press releases

From Benzinga Pro
Integrated BioPharma Announces Change in Directors
21 Jun 22
HILLSIDE, NJ / ACCESSWIRE / June 21, 2022 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") announced today Mr. Carl DeSantis has resigned as a Class I Director from the Company's
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2022
12 May 22
HILLSIDE, NJ / ACCESSWIRE / May 12, 2022 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the fiscal quarter ended March 31, 2022.Revenue for the

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 May 22
9 Aug 22
30 Jun 23

Financial summary

Financial statements Chart INBP financial data
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Jun 21 Jun 20 Jun 19 Jun 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Financial data from company earnings reports.

Recent insider trades

INBP insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
20 Jun 22 Robert Canarick Stock Option Common Stock Grant Acquire A No No 0 50,000 0 50,000
20 Jun 22 Milmoe William H. Stock Option Common Stock Grant Acquire A No No 0 50,000 0 50,000
20 Jun 22 Eric J Friedman Stock Option Common Stock Grant Acquire A No No 0 50,000 0 50,000
20 Jun 22 Damon DeSantis Stock Option Common Stock Grant Acquire A No No 0 50,000 0 50,000
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

INBP institutional ownership history Ownership history
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: ban, bore, calendar, cancelation, ceased, European, export, Gerald, imposition, Indonesia, Intercompany, Kay, Kingdom, largely, multinational, oil, palm, play, President, printed, reformulated, reformulation, role, Russia, strike, Sunflower, suspended, Ukraine, uncertain, unrelated, war
From filing 10-Q 2022 Q3
Financial reports
View all
10-Q
2022 Q3
Quarterly report
12 May 22
10-Q
2022 Q2
Quarterly report
10 Feb 22
10-Q
2021 Q1
Quarterly report
10 Nov 21
10-K
2021 FY
Annual report
2 Sep 21
10-Q
2021 Q3
Quarterly report
13 May 21
10-Q
2021 Q2
Quarterly report
12 Feb 21
10-Q
2021 Q1
Quarterly report
12 Nov 20
10-K
2020 FY
Annual report
23 Sep 20
10-Q
2020 Q3
Quarterly report
13 May 20
10-Q
2020 Q2
Quarterly report
12 Feb 20
Current reports
View all
8-K
Entry into a Material Definitive Agreement
15 Jul 22
8-K
Integrated BioPharma Announces Change in Directors
21 Jun 22
8-K
Results of Operations and Financial Condition
12 May 22
8-K
Results of Operations and Financial Condition
10 Feb 22
8-K
Submission of Matters to a Vote of Security Holders
29 Nov 21
8-K
Results of Operations and Financial Condition
10 Nov 21
8-K
Results of Operations and Financial Condition
2 Sep 21
8-K
Termination of a Material Definitive Agreement
7 Jul 21
8-K
Results of Operations and Financial Condition
13 May 21
8-K
Integrated BioPharma Announces Launch of Investors Website
8 Apr 21
Registration and prospectus
View all
S-8
Registration of securities for employees
28 Dec 18
D
$5.35M in debt / securities to be acquired, sold $5.35M, 1 investor
10 Jul 12
25
Voluntary exchange delisting
12 Apr 09
424B3
Prospectus supplement
5 May 08
S-3/A
Shelf registration (amended)
28 Apr 08
S-3/A
Shelf registration (amended)
16 Apr 08
S-3/A
Shelf registration (amended)
15 Apr 08
S-3
Shelf registration
20 Mar 08
REGDEX
Notice of sale of securities
6 Mar 08
RW
Registration withdrawal request
22 Aug 07
Proxies
View all
DEF 14A
Definitive proxy
27 Oct 21
DEF 14A
Definitive proxy
28 Oct 20
DEF 14A
Definitive proxy
28 Oct 19
DEF 14A
Definitive proxy
29 Oct 18
DEF 14A
Definitive proxy
26 Oct 17
DEF 14A
Definitive proxy
27 Oct 16
DEF 14A
Definitive proxy
25 Oct 15
DEF 14A
Definitive proxy
27 Oct 14
DEFA14A
Additional proxy soliciting materials
5 Nov 13
DEF 14A
Definitive proxy
27 Oct 13
Other
View all
UPLOAD
Letter from SEC
3 Aug 08
EFFECT
Notice of effectiveness
1 May 08
CORRESP
Correspondence with SEC
29 Apr 08
UPLOAD
Letter from SEC
21 Apr 08
UPLOAD
Letter from SEC
26 Mar 08
UPLOAD
Letter from SEC
26 Mar 08
UPLOAD
Letter from SEC
12 Mar 08
EFFECT
Notice of effectiveness
10 Jul 07
CORRESP
Correspondence with SEC
9 Feb 05
UPLOAD
Letter from SEC
17 Jan 05
Ownership
View all
4
INTEGRATED BIOPHARMA / Damon DeSantis ownership change
21 Jun 22
3
INTEGRATED BIOPHARMA / Damon DeSantis ownership change
21 Jun 22
4
INTEGRATED BIOPHARMA / ERIC J FRIEDMAN ownership change
21 Jun 22
4
INTEGRATED BIOPHARMA / William H. Milmoe ownership change
21 Jun 22
4
INTEGRATED BIOPHARMA / Robert Canarick ownership change
21 Jun 22
4/A
INTEGRATED BIOPHARMA / E GERALD KAY ownership change
11 May 22
4
INTEGRATED BIOPHARMA / E GERALD KAY ownership change
6 May 22
4
INTEGRATED BIOPHARMA / William H. Milmoe ownership change
4 Nov 21
4
INTEGRATED BIOPHARMA / CARL DESANTIS ownership change
4 Nov 21
4
INTEGRATED BIOPHARMA / E GERALD KAY ownership change
4 Nov 21